Santarus' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Santarus, Inc. (SNTS)

Q1 2012 Earnings Call

May 8, 2012 4:30 pm ET


Martha L. Hough – Vice President, Finance and Investor Relations

Gerald T. Proehl – President and Chief Executive Officer

Debra P. Crawford – Senior Vice President, Chief Financial Officer and Treasurer

William C. Denby, III – Senior Vice President, Commercial Operations

Wendell Wierenga – Executive Vice President, Research and Development


Frank Pinkerton – SunTrust Robinson Humphrey

Traver A. Davis – Piper Jaffray, Inc.

Annabel Samimy – Stifel, Nicolaus & Co., Inc.



Welcome to the Santarus Conference Call. At this time, all lines are in a listen-only mode. Following management’s prepared remarks, we’ll hold a question-and-answer session. (Operator Instructions) As a reminder, this conference is being recorded May 8, 2012.

I would now like to turn the call over to Martha Hough. Please go ahead, ma’am.

Martha L. Hough

Thank you, David. Good afternoon, and welcome to today’s call. This is Martha Hough, Vice President of Finance and Investor Relations. Joining me on the call today are Gerry Proehl, President and Chief Executive Officer; Debbie Crawford, Senior Vice President and Chief Financial Officer, and Bill Denby, Senior Vice President of Commercial Operations. Dr. Wendell Wierenga, Executive Vice President of Research and Development also will be available during the question-and-answer session.

Earlier today Santarus issued a press release announcing our first quarter 2012 financial results, which is available on our website at Also a replay of this call will be available for the next two weeks on the Investor Relations section of our website.

Please keep in mind that risks and uncertainties involved in the company’s business may affect the matters referred to in forward-looking statements made by management during today’s call. As a result, the company’s performance may differ from those expressed in or indicated by such forward-looking statements, which are qualified in their entirety by the cautionary statements contained in the press release and the company’s Securities and Exchange Commission filings.

If you liked this article you might like

Investors Expect too Much of Salix

The Deal: Salix Pharmaceuticals Buys Santarus for $2.6B

Santarus (SNTS): Heavy Pre-Market Activity

Salix Pharma to Acquire Santarus

Insider Trading Alert - Santarus And 4 Others Traded By Insiders